Residency · Residency · Cardiothoracic Surgery

Prosthetic Valve Selection and Management

Overview

Prosthetic valve selection is among the most consequential shared decisions between surgeon and patient. The choice between mechanical and bioprosthetic valves involves balancing durability against anticoagulation burden, lifestyle considerations, and the increasingly relevant option of future transcatheter valve-in-valve intervention. This chapter covers valve types, selection criteria, complications, and the evolving "lifetime management" strategy.

Types of Prosthetic Valves

Mechanical Valves

Current bileaflet tilting disc designs (St. Jude Medical Regent, On-X) are the most commonly used, featuring two semicircular pyrolytic carbon leaflets that open to approximately 85 degrees and provide excellent hemodynamics with low transvalvular gradients. Older designs (caged-ball Starr-Edwards, single tilting disc Bjork-Shiley and Medtronic Hall) are still encountered in patients with previously implanted valves. Mechanical valves offer virtually unlimited durability (30+ years documented), but require lifelong warfarin anticoagulation. They produce an audible closing click that may bother some patients.

Anticoagulation requirements vary by position. The aortic position targets INR 2.0-3.0, with the On-X valve uniquely approved for INR 1.5-2.0 after 3 months with aspirin (per the PROACT trial). The mitral position targets INR 2.5-3.5. When both positions are involved or additional risk factors are present, INR 2.5-3.5 is targeted. Bridging with heparin is required for invasive procedures. Novel oral anticoagulants (DOACs) are absolutely contraindicated with mechanical valves — the RE-ALIGN trial demonstrated increased thromboembolism and bleeding with dabigatran.

Bioprosthetic Valves

Bovine pericardial valves (such as the Edwards Perimount Magna Ease and Edwards Inspiris RESILIA) are the most commonly used, featuring treated pericardium mounted on a stent frame with excellent hemodynamics. Porcine valves (Medtronic Hancock II, Medtronic Mosaic) use whole porcine aortic valves mounted on stent frames, with slightly higher gradients. Stentless valves (Medtronic Freestyle) offer superior hemodynamics but are technically more demanding to implant.

Bioprosthetic valves have limited durability (10-20 years depending on patient age and valve position) but require no long-term anticoagulation (aspirin alone). They are susceptible to structural valve deterioration (SVD). The Edwards Inspiris RESILIA uses anti-calcification technology and is designed for compatibility with future valve-in-valve TAVR.

Mechanical vs. Bioprosthetic Valve Comparison

Homograft (Allograft) Valves

Cryopreserved human aortic or pulmonary valves offer excellent hemodynamics and resistance to infection. They are preferred in aortic root endocarditis with abscess. Availability is limited by cadaveric donor supply, and SVD occurs, especially in younger patients.

Autograft (Ross Procedure)

The pulmonary autograft in the aortic position, with a homograft replacing the pulmonary valve, provides living tissue with growth potential and no anticoagulation requirement. It may be ideal for young, active patients, though concerns about neoaortic root dilatation and the creation of a two-valve problem exist.

Valve Selection Decision-Making

Factors to Consider

Key factors include patient age and life expectancy, anticoagulation tolerance (compliance, bleeding risk, fall risk, lifestyle), desire for pregnancy (warfarin is Category X teratogenic), activity level (mechanical valve patients must avoid contact sports), comorbidities (renal failure accelerates SVD, liver disease impairs anticoagulation), patient preference (the single most important factor after risk-benefit counseling), and valve-in-valve TAVR availability.

Current Guidelines (ACC/AHA 2020)

Mechanical valves are reasonable for patients under 50 (aortic) or under 65 (mitral) without contraindications to anticoagulation. Bioprosthetic valves are reasonable for patients over 65 or those with contraindications to anticoagulation. The age 50-65 range for the aortic position is a shared decision-making zone where either option is acceptable. The threshold for bioprosthetic valves has shifted younger due to valve-in-valve TAVR options.

The "Lifetime Management" Strategy

Modern valve selection plans the patient's entire valve career at the first operation. A 45-year-old receiving a bioprosthetic valve may need: the initial SAVR (age 45), valve-in-valve TAVR (age 60-65), and possibly a re-do TAVR or SAVR (age 75-80). This strategy requires the initial bioprosthesis to have adequate internal diameter for future valve-in-valve procedures, avoiding patient-prosthesis mismatch at each stage.

Prosthetic Valve Complications

Thromboembolism

Mechanical valves carry a 1-2% per year risk with adequate anticoagulation. Bioprosthetic valves carry less than 0.5% per year, though subclinical leaflet thrombosis is increasingly recognized on CT imaging. Risk factors include atrial fibrillation, low cardiac output, subtherapeutic INR, and LA smoke or thrombus.

Valve Thrombosis

More common with mechanical valves (especially with subtherapeutic anticoagulation), valve thrombosis presents with increased gradients, new symptoms, and decreased valve click. Diagnosis is made by fluoroscopy (restricted leaflet motion) and TEE (thrombus, elevated gradients). Treatment options include IV heparin, thrombolytics, or surgical thrombectomy/replacement depending on severity.

Structural Valve Deterioration (SVD) — Bioprosthetic

SVD progresses through calcification, leaflet tears, or pannus formation. The rate depends heavily on patient age: patients under 40 have 50% SVD at 10 years, those aged 40-60 have 20-30% at 15 years, and those over 70 have less than 10% at 15 years. Treatment is re-do SAVR or valve-in-valve TAVR.

Paravalvular Leak (PVL)

Suture dehiscence from the annulus creates a periprosthetic regurgitant jet, caused by annular calcification, infection, tissue friability, or technical error. Mild PVL is common and usually benign. Significant PVL causes hemolysis and heart failure and requires repair or closure (surgical or transcatheter).

Prosthetic Valve Endocarditis (PVE)

PVE occurs in 1-6% of prosthetic valves. Early PVE (within 1 year) involves nosocomial organisms (Staph aureus, coagulase-negative Staph, fungi) and is typically virulent. Late PVE (beyond 1 year) resembles native valve endocarditis in its microbiology. Surgery is indicated for heart failure, uncontrolled infection, abscess, recurrent emboli, fungal PVE, and prosthetic dehiscence.

Prosthetic Valve Complications Summary

Hemolysis

Chronic low-grade hemolysis occurs with all mechanical valves but is subclinical. Clinically significant hemolysis suggests paravalvular leak, valve malfunction, or ball variance. Monitoring includes LDH, haptoglobin, reticulocyte count, and peripheral smear for schistocytes.

<image>Visual comparison of prosthetic heart valve types. Four panels show: (A) bileaflet mechanical valve (St. Jude type) with carbon leaflets in open and closed positions, (B) stented bioprosthetic pericardial valve (Edwards Perimount type) showing tissue leaflets and stent posts, (C) stentless porcine bioprosthetic valve (Freestyle type) showing the intact porcine root, and (D) a cryopreserved homograft valve. Below each valve, a summary table lists: durability, anticoagulation needs, hemodynamic profile, and key advantages/disadvantages. A central timeline graphic shows the expected lifespan curves for mechanical versus bioprosthetic valves by patient age.</image>

<image>Algorithm for prosthetic valve selection based on patient age and clinical factors. The flowchart starts with patient age categories (less than 50, 50-65, greater than 65), incorporates key decision modifiers (anticoagulation tolerance, pregnancy planning, bleeding risk, activity level, renal failure), and leads to recommended valve type. A parallel "lifetime management" pathway shows the projected valve career for a young patient choosing a bioprosthetic strategy: initial SAVR, future valve-in-valve TAVR, and potential third intervention, with approximate ages and expected valve durability at each stage.</image>

Surveillance After Valve Replacement

Echocardiographic Monitoring

A baseline TTE within 30 days of surgery establishes reference gradients and EOA. Annual TTE is recommended for bioprosthetic valves to detect early SVD. TTE should be obtained for any new symptoms, change in murmur, or suspected valve dysfunction. Mechanical valves require TTE as needed, with less urgency for routine annual imaging given their durability.

Anticoagulation Monitoring

Mechanical valve patients require regular INR monitoring (in-clinic or home testing). Bridge anticoagulation with low-molecular-weight heparin or IV heparin is needed for invasive procedures. Antibiotic prophylaxis before dental procedures remains recommended for all prosthetic valve patients.

Clinical Pearls

DOACs are absolutely contraindicated with mechanical valves — the RE-ALIGN trial showed increased thromboembolism and bleeding with dabigatran. The On-X valve is unique in allowing a lower INR target (1.5-2.0) in the aortic position after 3 months, based on the PROACT trial. The age threshold for bioprosthetic valve selection continues to shift younger (now approximately 50 years for the aortic position) because valve-in-valve TAVR provides a viable re-intervention strategy. Every bioprosthetic valve implanted today should be selected with future valve-in-valve TAVR in mind, and adequate internal diameter is essential to avoid PPM at the second intervention. Subclinical leaflet thrombosis on bioprosthetic valves is increasingly recognized on CT imaging; its clinical significance remains debated. Patient-prosthesis mismatch is preventable and the surgeon's responsibility. Prosthetic valve endocarditis in the first year is usually nosocomial and virulent — early surgical consultation is critical.

References

• Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for Valvular Heart Disease. Circulation. 2021;143(5):e72-e227.
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Trial: Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-1214.
• Puskas JD, Gerdisch M, Nichols D, et al. PROACT Trial: Reduced anticoagulation after mechanical aortic valve replacement. J Thorac Cardiovasc Surg. 2014;147(4):1202-1211.
• Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312(2):162-170.
• Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017;38(28):2183-2191.

Read this lecture as Markdown